Yatin Suneja
Stock Analyst at Guggenheim
(3.21)
# 1,359
Out of 4,667 analysts
106
Total ratings
48.28%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $585 → $665 | $591.82 | +12.37% | 8 | Nov 1, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Buy | $50 → $65 | $27.50 | +136.36% | 1 | Oct 25, 2024 | |
| ANAB AnaptysBio | Maintains: Buy | $75 → $90 | $20.31 | +343.13% | 10 | Oct 21, 2024 | |
| ZBIO Zenas BioPharma | Initiates: Buy | $45 | $12.45 | +261.45% | 1 | Oct 8, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Buy | $17 → $16 | $3.05 | +424.59% | 2 | Aug 14, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $155 → $170 | $73.68 | +130.73% | 2 | Aug 14, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $170 → $180 | $123.29 | +46.00% | 3 | Aug 2, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,180 → $1,300 | $743.35 | +74.88% | 5 | Aug 2, 2024 | |
| ALMS Alumis | Initiates: Buy | $32 | $9.64 | +231.95% | 1 | Jul 23, 2024 | |
| QTTB Q32 Bio | Initiates: Buy | $100 | $27.28 | +266.57% | 1 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.07 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $8.86 | +464.33% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $26.40 | +240.91% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $94.60 | +32.14% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $32 | $59.77 | -46.46% | 3 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $11.49 | +39.25% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $49.82 | +54.56% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.00 | +108.33% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $9.79 | +124.72% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $26.17 | +22.28% | 5 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 | $2.26 | +1,404.42% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.59 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.90 | +589.66% | 1 | Jun 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $39.34 | +24.56% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $8.96 | +514.18% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $6.08 | +130.26% | 3 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $156.00 | +124.36% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.04 | - | 4 | Apr 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 | $16.27 | +35.22% | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.91 | - | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.90 | - | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $30 | $8.73 | +243.64% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.85 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $19.38 | +23.84% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $38.85 | -12.48% | 2 | Jan 14, 2020 |
argenx SE
Nov 1, 2024
Maintains: Buy
Price Target: $585 → $665
Current: $591.82
Upside: +12.37%
Spyre Therapeutics
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $27.50
Upside: +136.36%
AnaptysBio
Oct 21, 2024
Maintains: Buy
Price Target: $75 → $90
Current: $20.31
Upside: +343.13%
Zenas BioPharma
Oct 8, 2024
Initiates: Buy
Price Target: $45
Current: $12.45
Upside: +261.45%
Vigil Neuroscience
Aug 14, 2024
Maintains: Buy
Price Target: $17 → $16
Current: $3.05
Upside: +424.59%
Praxis Precision Medicines
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $73.68
Upside: +130.73%
Neurocrine Biosciences
Aug 2, 2024
Maintains: Buy
Price Target: $170 → $180
Current: $123.29
Upside: +46.00%
Regeneron Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $1,180 → $1,300
Current: $743.35
Upside: +74.88%
Alumis
Jul 23, 2024
Initiates: Buy
Price Target: $32
Current: $9.64
Upside: +231.95%
Q32 Bio
Jun 17, 2024
Initiates: Buy
Price Target: $100
Current: $27.28
Upside: +266.57%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
Apr 29, 2024
Initiates: Buy
Price Target: $50
Current: $8.86
Upside: +464.33%
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $26.40
Upside: +240.91%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $94.60
Upside: +32.14%
Jan 2, 2024
Maintains: Buy
Price Target: $16 → $32
Current: $59.77
Upside: -46.46%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $11.49
Upside: +39.25%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $49.82
Upside: +54.56%
Oct 31, 2023
Initiates: Buy
Price Target: $50
Current: $24.00
Upside: +108.33%
Oct 10, 2023
Initiates: Buy
Price Target: $22
Current: $9.79
Upside: +124.72%
Sep 22, 2023
Reiterates: Buy
Price Target: $32
Current: $26.17
Upside: +22.28%
Aug 14, 2023
Reiterates: Buy
Price Target: $34
Current: $2.26
Upside: +1,404.42%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $0.59
Upside: -
Jun 22, 2023
Initiates: Buy
Price Target: $20
Current: $2.90
Upside: +589.66%
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $39.34
Upside: +24.56%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $8.96
Upside: +514.18%
May 17, 2023
Maintains: Buy
Price Target: $12 → $14
Current: $6.08
Upside: +130.26%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $156.00
Upside: +124.36%
Apr 6, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.04
Upside: -
Jan 3, 2023
Upgrades: Buy
Price Target: $22
Current: $16.27
Upside: +35.22%
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.91
Upside: -
Nov 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.90
Upside: -
Nov 11, 2022
Maintains: Buy
Price Target: $42 → $30
Current: $8.73
Upside: +243.64%
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.85
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $19.38
Upside: +23.84%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $38.85
Upside: -12.48%